-

03:48:54 PM

ITRM Stock News

ITRM - Iterum Therapeutics Plc

09/28/21 8:00 AM

Nasdaq : ITRM

Iterum Therapeutics Provides Update from FDA Type A Meeting Regarding Oral Sulopenem

Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both

RHEA-AI

neutral

09/28/21 7:30 AM

Nasdaq : ITRM

conferences

Iterum Therapeutics to Present Data at IDWeek 2021

Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both

RHEA-AI

neutral

09/27/21 12:15 PM

Nasdaq : ITRM

ITERUM THERAPEUTICS PLC (NASDAQ: ITRM) OCTOBER 4, 2021 INVESTOR FILING DEADLINE:

Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of

RHEA-AI

negative

09/08/21 8:55 AM

Nasdaq : ITRM

conferences

Iterum Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both

RHEA-AI

neutral

08/13/21 7:00 AM

Nasdaq : ITRM

earnings

Iterum Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update

DUBLIN, Ireland and CHICAGO, Aug. 13, 2021 (GLOBE

RHEA-AI

neutral

08/06/21 7:00 AM

Nasdaq : ITRM

earnings

Iterum Therapeutics to Provide Business Update and Report Second Quarter 2021 Financial Results on August 13, 2021

Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community

RHEA-AI

neutral

07/26/21 7:00 AM

Nasdaq : ITRM

Iterum Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration for Oral Sulopenem

Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both

RHEA-AI

neutral

07/01/21 6:30 PM

Nasdaq : ITRM

Iterum Therapeutics Provides Regulatory Update

Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both

RHEA-AI

neutral

05/27/21 5:00 PM

Nasdaq : ITRM

Iterum Therapeutics Provides Update on NDA Review

Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both

RHEA-AI

neutral

05/14/21 7:00 AM

Nasdaq : ITRM

earnings

Iterum Therapeutics Reports First Quarter 2021 Financial Results

Iterum Therapeutics plc

RHEA-AI

neutral

ITRM Data:

IndustryPharmaceutical Preparation Manufacturing
Websitewww.iterumtx.com
Security nameIterum Therapeutics Plc
Issue typecs
SectorManufacturing
Sic code2834
Employees7
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing

ITRM Description:

Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum Therapeutics is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum Therapeutics has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications.